Blog
RSS FeedPosted by Michael Wonder on 20 May 2021
NICE turns down Janssen's Erleada
20 May 2021 - NICE has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy for treating prostate ...
Posted by Michael Wonder on 20 May 2021
Katie Porter brings her whiteboard to accuse pharma CEO of inflating drug prices
19 May 2021 - Rep. Katie Porter (D-Calif.) went viral on social media after she brought back her signature whiteboard ...
Posted by Michael Wonder on 20 May 2021
Budget 2021: Health boost for PHARMAC and funding for Māori Health Authority
20 May 2021 - Health Minister Andrew Little said it was one of the biggest increases PHARMAC had ever had ...
Posted by Michael Wonder on 20 May 2021
Patients with rare blood disorders to receive new treatment option, says NICE
20 May 2021 - Hundreds of people with two rare blood disorders will soon have access to a new treatment regimen ...
Posted by Michael Wonder on 20 May 2021
Boring Budget 2021 reinforces two tier medicines access system in New Zealand
20 May 2021 - Announcement in the budget today of $200 million over the next four years is simply meeting the ...
Posted by Michael Wonder on 20 May 2021
PHARMAC political theatre grotesque
20 May 2021 - “It is grotesque political theatre to make people wait for the budget to get their medicines ...
Posted by Michael Wonder on 19 May 2021
Leading real world data and analytics organisations form industry coalition to advance policies to support regulatory use of real world evidence
19 May 2021 - RWE Alliance Launched by Aetion, Flatiron Health, IQVIA, Syapse, and Tempus. ...
Posted by Michael Wonder on 19 May 2021
Will AbbVie, maker of the world’s best-selling drug, finally face the music over its price hikes?
20 May 2021 - If you're looking for a story which encapsulates the duality of the pharmaceutical industry, you don't have ...
Posted by Michael Wonder on 19 May 2021
BioXcel Therapeutics announces FDA acceptance for filing of NDA for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II
19 May 2021 - FDA sets PDUFA action date for 5 January 2022. ...
Posted by Michael Wonder on 19 May 2021
BeiGene announces U.S. FDA acceptance and priority review of supplemental new drug application for Brukinsa (zanubrutinib) in marginal zone lymphoma
19 May 2021 - BeiGene today announced that the U.S. FDA has accepted a supplemental new drug application for Brukinsa ...
Posted by Michael Wonder on 19 May 2021
‘Use effective drugs in early multiple myeloma to prevent relapse’
19 May 2021 - Multiple myeloma patients suffer frequent recurrences, and treatment response rates and response durations plummet along with ...
Posted by Michael Wonder on 19 May 2021
Pfizer withdraws evidence submission for Staquis
19 May 2021 - NICE is unable to make a recommendation on the use of crisaborole for the treatment of people ...
Posted by Michael Wonder on 19 May 2021
FDA launches crowdsourcing challenge to solicit input on research questions to be addressed through FDA's oncologic clinical trial data
18 May 2021 - Today, the U.S. FDA's Oncology Center of Excellence launched the “Send Your Oncology Research Questions to ...
Posted by Michael Wonder on 19 May 2021
NICE terminates yet another appraisal of a cancer medicine
19 May 2021 - This time it is for a new medicine for patients with multiple myeloma. ...
Posted by Michael Wonder on 18 May 2021
Northern Ireland faces ‘huge’ rise in generic medicine prices
18 May 2021 - Large increase likely after end of Brexit grace period, warns UUP head Simon Aiken. ...